147 related articles for article (PubMed ID: 15116053)
1. Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
3. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
4. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
5. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
7. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
Allabi AC; Horsmans Y; Alvarez JC; Bigot A; Verbeeck RK; Yasar U; Gala JL
Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):125-32. PubMed ID: 21811894
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi H; Wilkinson GR; Padrini R; Echizen H
Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
[No Abstract] [Full Text] [Related]
12. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
[TBL] [Abstract][Full Text] [Related]
13. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
16. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
17. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.
van Schie RM; Wessels JA; Verhoef TI; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; Visser LE; Teichert M; Hofman A; Buhre PN; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2012 Dec; 13(16):1917-23. PubMed ID: 23215884
[TBL] [Abstract][Full Text] [Related]
20. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
